2. Academic Validation
  3. Phosphoglycerate kinase 1 contributes to diabetic kidney disease through enzyme-dependent and independent manners

Phosphoglycerate kinase 1 contributes to diabetic kidney disease through enzyme-dependent and independent manners

  • Cell Rep Med. 2025 Aug 19;6(8):102241. doi: 10.1016/j.xcrm.2025.102241.
Hai-Jian Sun 1,  Qing-Bo Lu 2,  Shi-Jia Liu 3,  Xiao Fu 1,  Cheng-Li Yu 4,  Jia-Bao Su 5,  Xin-Yu Meng 1,  Xi Guo 6,  Xin Shao 7,  Jun-Hui Li 8,  Qing-Yi Sun 1,  Xue-Xue Zhu 9,  Jin-Jun Shan 10,  Wei Zhou 11
Affiliations

Affiliations

  • 1 Departement of Basic Medicine, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu 214122, China.
  • 2 Department of Endocrinology, Affiliated Hospital of Jiangnan University, Jiangnan University, Wuxi 214125, China.
  • 3 Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu 210029, China.
  • 4 School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
  • 5 Department of Anesthesiology, Affiliated Hospital of Jiangnan University, Jiangnan University, Wuxi 214122, China.
  • 6 State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
  • 7 Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing 210023, China.
  • 8 Department of Nephrology, Putuo People's Hospital, Tongji University School of Medicine, Shanghai 200060, China.
  • 9 Departement of Basic Medicine, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu 214122, China. Electronic address: zhuxuexue117@163.com.
  • 10 Institute of Pediatrics, Jiangsu Key Laboratory of Pediatric Respiratory Disease, Medical Metabolomics Center, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China. Electronic address: jshan@njucm.edu.cn.
  • 11 State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, China. Electronic address: wzhou@cpu.edu.cn.
PMID: 40695289 DOI: 10.1016/j.xcrm.2025.102241
Abstract

Diabetic kidney disease (DKD) is characterized by abnormal metabolic profiles. Metabolomics reveals increased serum levels of 3-phosphoglycerate (3-PG) in DKD patients. The protein expression of phosphoglycerate kinase 1 (PGK1), a key rate-limiting enzyme for 3-PG synthesis, is concomitantly upregulated in DKD patients and mice. The development of DKD is significantly mitigated by renal tubular epithelial cell-specific knockout of PGK1 and robustly worsened by PGK1 overexpression. Mechanistically, PGK1-dependent enzymatic production of 3-PG facilitates DKD through inhibiting GPX1 to activate the NLRP3 inflammasome. PGK1 promotes UNC5CL-mediated inflammation by binding to aldehyde dehydrogenase-1 L1 (Aldh1l1) through its non-enzymatic activity. The transcription factor paired box protein 5 (PAX5) mediates the upregulation of PGK1 in DKD. High-throughput screening reveals that C-16 from ChemDiv, the natural product lirinidine, and the Food and Drug Administration (FDA)-approved oxantel pamoate are potent PGK1 antagonists and efficaciously prevent DKD. Overall, blocking PGK1 may be a promising avenue for DKD management.

Keywords

3-phosphoglycerate; NLRP3; PGK1; diabetic kidney disease; drug screening; inflammation; metabolomics; oxidative stress.

Figures
Products